In comparison with the ERSPC
trial, after 13-years, the rate of over-diagnosis leading to over-treatment was 40%, yet there was no reduction in all-cause mortality (Schroder et al., 2014).
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC
and PLCO Trials.
Following the release of PLCO and ERSPC
data, our centre conducted a survey of over 900 primary care physicians (PCPs) in Ontario with respect to their prostate cancer screening practices.
Now, a recent analysis suggests that, after accounting for difference between the two studies, the PLCO and ERSPC
both show a survival benefit to prostate cancer screening.
study did find a reduction, albeit small--an absolute reduction in mortality in screened men of only 0.1 death per 1,000 person-years, or 1.07 deaths per 1,000 men.
The European Randomized Study of Screening for Prostate Cancer (ERSPC
) trial reported that PSA screening was associated with a 20% relative reduction in prostate cancer mortality at a median follow-up of 9 years, resulting in reduction of about 7 prostate cancer deaths per 10,000 men screened .
An important finding in our study, however, is that two patients with prostate hypermetabolism and a PSA below the typical cutoff of 4ng/mL used in large screening trials, ERSPC
, and PLCO [14,15] were found to have occult prostate cancer.
(5.) Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, ERSPC
In the multicenter Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (2) conducted in the United States, there was a nonsignificant increase in prostate-cancer mortality in the screening group, while the European Randomized Study of Screening for Prostate Cancer (ERSPC
) (3) trial showed a statistically significant absolute reduction of 0.10 prostate-cancer deaths per 1000 person-years after a median follow-up of 11 years.
Bu konuyu arastiran buyuk olcekli 4 toplum calismasi vardir: Prostat, Akciger, Kolorektal ve Over kanseri tarama (The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial) calismasi, Avrupa Prostat Kanseri Taramasi Randomize calismasi (ERSPC
On the other hand, data from the "European Randomized Study of Screening for Prostate Cancer" (ERSPC
) suggests that PSA-based screening reduced the rate of death from prostate cancer by 20% .
Researchers applied complex modeling to the European Randomized Study of Screening for Prostate Cancer (ERSPC
), which reported screening cuts prostate cancer mortality by 29%.